With the surge of investments, RFCL looks forward to grow at a CAGR of
23 percent in next four years
Sushil Mehta (MD)
Life Sciences Business
Manufactures and markets fine chemicals and lab kits
A-3, Okhla Industrial area, Phase-I, New Delhi-110020
(in Rs Crore)
Rs 93.23 Crore
RFCL is aggressively building its business with the support of
R&D, product development and manufacturing to offer value-added products and services
to the customers
RFCL Limited, owned by ICICI Venture Funds Management Company and managed by a group of professionals,
focuses on two strategic business units – Rankem Scientific Laboratory Solutions and Diagnova. These
two business segments cover a range of customer segments including pharma, biotech, R&D labs, food
processing, in vitro diagnostic facilities in clinical labs, hospitals, and nursing homes.
RFCL has recorded a CAGR of over 25 percent in sales revenue for the last four years. However, for
the fiscal 2009-10, the company's revenue stood at Rs 93.23 crore as compared to Rs 92.21 crore last
year, when the company had achieved a phenomenal growth clocking Rs 34.04 crore in fiscal 2007-08.
Driven by its vision of “Leveraging science to provide solutions for a better life”, RFCL is
aggressively building both its businesses backed by R&D, product development and manufacturing
to offer value added products and services to its target customers. The company has recently
unveiled its new mid-term plan, Sprint 2014, which will enable RFCL to grow at a CAGR of 23 percent
for the next four years.
In micro-life portfolio (dehydrated culture media), Rankem has added 64 products, which will
give wider spectrum to different application areas.
In molecular biology segment, the addition of 47 products will be completing the basket of fermentation
area, where the purity and accuracy is now defined at upstream process. According to new practices in
fermentation technology, now more emphasis is given to upstream process to reduce the end product cost
and to increase efficiency of the drug.
RFCL also entered into a strategic partnership with Integrated DNA Technologies (IDT), US, for the
marketing of custom nucleic acids to the Indian researchers.
The company has plans to invest on building in-house manufacturing for diagnostic products and
laboratory chemicals. The company has already commissioned a dedicated manufacturing plant for
diagnostics in Dehradun.
In addition, a new lab chemical manufacturing plant is currently under erection stages at Panoli,